Subgroup analysis of patients with G2 gastroenteropancreatic neuroendocrine tumors

References

• Yao JC, Hassan M, Phan A, Dagohoy C, Leary C, Mares JE, et al. One hundred years after ‘carcinoid’: epidemiology of and prognostic factors for neuroendocrine tumors in 35 825 cases in the United States. J Clin Oncol 2008;26:3063–72.
   PubMed Web of Science ®Google Scholar
• Hemminki K, Li X. Incidence trends and risk factors of carcinoid tumors: a nationwide epidemiologic study from Sweden. Cancer 2001;92:2204–10.
   PubMed Web of Science ®Google Scholar
• Ellis L, Shale MJ, Coleman MP. Carcinoid tumors of the gastrointestinal tract: trends in incidence in England since 1971. Am J Gastroenterol 2010;105:2563–9.
   PubMed Web of Science ®Google Scholar
• Hallet J, Law CH, Cukier M, Saskin R, Liu N, Singh S. Exploring the rising incidence of neuroendocrine tumors: A population-based analysis of epidemiology, metastatic presentation, and outcomes. Cancer 2015;121:589–97.
   PubMed Web of Science ®Google Scholar
• O’Connor JM, Marmissolle F, Bestani C, Pesce V, Belli S, Dominichini E, et al. Observational study of patients with gastroenteropancreatic and bronchial neuroendocrine tumors in Argentina: Results from the large database of a multidisciplinary group clinical multicenter study. Mol Clin Oncol 2014;2:673–84.
   PubMedGoogle Scholar
• Hauso O, Gustafsson BI, Kidd M, Waldum HL, Drozdov I, Chan AK, et al. Neuroendocrine tumor epidemiology: contrasting Norway and North America. Cancer 2008;113:2655–64.
   PubMed Web of Science ®Google Scholar
• Massironi S, Sciola V, Peracchi M, Ciafardini C, Spampatti MP, Conte D. Neuroendocrine tumors of the gastro-entero-pancreatic system. World J Gastroenterol 2008;14:5377–84.
   PubMed Web of Science ®Google Scholar
• Rinke A, Michl P, Gress T. Medical treatment of gastroenteropancreatic neuroendocrine tumors. Cancers 2012;4:113–29.
   PubMedGoogle Scholar
• Yao JC, Shah MH, Ito T, Bohas CL, Wolin EM, Van Cutsem E, et al. RAD001 in advanced neuroendocrine tumors, third trial (RADIANT-3) Study Group. Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med 2011;364:514–23.
   PubMed Web of Science ®Google Scholar
• Chan J, Kulke M. Targeting the mTOR signaling pathway in neuroendocrine tumors. Curr Treat Options Oncol 2014;15:365–79.
   PubMed Web of Science ®Google Scholar
• Baldelli R, Barnabei A, Rizza L, Isidori AM, Rota F, Di Giacinto P, et al. Somatostatin analogs therapy in gastroenteropancreatic neuroendocrine tumors: current aspects and new perspectives. Front Endocrinol 2014;5:7.
   PubMed Web of Science ®Google Scholar
• van der Zwan WA, Bodei L, Mueller-Brand J, de Herder WW, Kvols LK, Kwekkeboom DJ. GEPNETs update: Radionuclide therapy in neuroendocrine tumors. Eur J Endocrinol 2015;172:R1–8.
   Google Scholar
• van Vliet EI, Teunissen JJ, Kam BL, de Jong M, Krenning EP, Kwekkeboom DJ. Treatment of gastroenteropancreatic neuroendocrine tumors with peptide receptor radionuclide therapy. Neuroendocrinology 2013;97:74–85.
   PubMed Web of Science ®Google Scholar
• Rossi RE, Burroughs AK, Caplin ME. Liver transplantation for unresectable neuroendocrine tumor liver metastases. Ann Surg Oncol 2014;21:2398–405.
   PubMed Web of Science ®Google Scholar
• Fendrich V, Bartsch DK. Surgical treatment of gastrointestinal neuroendocrine tumors. Langenbecks Arch Surg 2011;396:299–311.
   PubMed Web of Science ®Google Scholar
• Strosberg JR. Systemic. treatment of gastroenteropancreatic neuroendocrine tumors (GEP-NETS): current approaches and future options. Endocr Pract 2014;20:167–75.
   PubMed Web of Science ®Google Scholar
• O’Toole D, Hentic O, Corcos O, Ruszniewski P. Chemotherapy for gastro-enteropancreatic endocrine tumours. Neuroendocrinology 2004;80:79–84.
   PubMedGoogle Scholar
• Raymond E, Dahan L, Raoul JL, Bang YJ, Borbath I, Lombard-Bohas C, et al. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med 2011;364:501–13.
   PubMed Web of Science ®Google Scholar
• Modlin IM, Pavel M, Kidd M, Gustafsson BI. Review article: somatostatin analogues in the treatment of gastroenteropancreatic neuroendocrine (carcinoid) tumours. Aliment Pharmacol Ther 2010;31:169–88.
   PubMed Web of Science ®Google Scholar
• Moertel CG, Lefkopoulo M, Lipsitz S, Hahn RG, Klaassen D. Streptozocin-doxorubicin, streptozocin-fluorouracil or chlorozotocin in the treatment of advanced islet-cell carcinoma. N Engl J Med 1992;326:519–23.
   PubMed Web of Science ®Google Scholar
• Williams ED, Sandler M. The classification of carcinoid tumours. Lancet 1963;238–9.
   PubMed Web of Science ®Google Scholar
• Rindi G, Arnold R, Bosman F, Capella C, Klimstra D, Klöppel G, et al. Nomenclature and classification of neuroendocrine neoplasms of the digestive system. In Bosman F, Carneiro F, Hruban R, Theise N, Editors WHO Classification of Tumours of the Digestive System. 4th edition. Lyon: International Agency for Research on Cancer; 2010. pp 13–14.
   Google Scholar
• Jamali M, Runjan C. Predicting prognosis in gastroentero- pancreatic neuroendocrine tumors: an overview and the value of Ki-67 immunostaining. Endocr Pathol 2008;19:282–8.
   PubMed Web of Science ®Google Scholar
• Scholzen T, Gerdes J. The Ki-67 Protein: from the known and the unknown. J Cell Physiol 2000;182:311–22.
   PubMed Web of Science ®Google Scholar
• Klimstra DS, Modlin IR, Coppola D, Lloyd RV, Suster S. The pathologic classification of neuroendocrine tumors: a review of nomenclature, grading and staging systems. Pancreas 2010;39:707–12.
   PubMed Web of Science ®Google Scholar
• Kloppel G, Couvelard A, Perren A, Komminoth P, McNicol AM, Nilsson O, et al. ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: towards a standardized approach to the diagnosis of gastroenteropancreatic neuroendocrine tumors and their prognostic stratification. Neuroendocrinology 2009;90:162–6.
   PubMed Web of Science ®Google Scholar
• Ekeblad S, Skogseid B, Dunder K, Oberg K, Eriksson B. Prognostic factors and survival in 324 patients with pancreatic endocrine tumor treated at a single institution. Clin Cancer Res 2008;14:7798–803.
   PubMed Web of Science ®Google Scholar
• Rindi G, D’Adda T, Froio E, Fellegara G, Bordi C. Prognostic factors in gastrointestinal endocrine tumors. Endocr Pathol 2007;18:145–9.
   PubMed Web of Science ®Google Scholar
• Martin-Perez E, Capdevila J, Castellano D, Jimenez-Fonseca P, Salazar R, Beguiristain-Gomez A, et al. Prognostic factors and long-term outcome of pancreatic neuroendocrine neoplasms: Ki-67 index shows a greater impact on survival than disease stage. The large experience of the Spanish National Tumor Registry (RGETNE). Neuroendocrinology 2013;98:156–68.
   PubMed Web of Science ®Google Scholar
• Massironi S, Sciola V, Peracchi M, Ciafardini C, Spampatti MP, Conte D. Neuroendocrine tumors of the gastro-entero-pancreatic system. World J Gastroenterol 2008;14:5377–84.
   PubMed Web of Science ®Google Scholar
• Eads JR, Meropol NJ. A new era for the systemic therapy of neuroendocrine tumors. Oncologist 2012;17:326–38.
   PubMed Web of Science ®Google Scholar
• Spitzweg C, Göke B. Therapy of endocrine gastrointestinal tumors. Internist (Berl) 2002;43:219–29.
   PubMed Web of Science ®Google Scholar
• Pujol JL, Quantin X, Jacot W, Boher JM, Grenier J, Lamy PJ. Neuroendocrine and cytokeratin serum markers as prognostic determinants of small cell lung cancer. Lung Cancer 2003;39:131–8.
   PubMed Web of Science ®Google Scholar
• Iyoda A, Hiroshima K, Toyozaki T, Haga Y, Fujisawa T, Ohwada H. Clinical characterization of pulmonary large cell neuroendocrine carcinoma and large cell carcinoma with neuroendocrine morphology. Cancer 2001;91:1992–2000.
   PubMed Web of Science ®Google Scholar